Avacta and Glythera to jointly develop alternative to antibody drug conjugates

14 July 2016

Avacta Group (LSE: AVCT), the provider of research reagents, consumables and equipment for life scientists, and biotech company Glythera believe they can develop a class of highly targeted bio-therapeutics as a superior alternative to the established class of antibody drug conjugates (ADCs).

That is the stated aim of the newly-announced collaboration between the UK-based companies, which will see them evaluate the use of Glythera’s PermaLink conjugation chemistry in combination with Avacta’s Affimer technology.

ADCs use an antibody to which a toxin/chemotherapy payload is chemically attached for targeted delivery to a tumor. More than 50 of these conjugates are currently in clinical development and of these, approximately a quarter are in Phase II or Phase III. The market is estimated to be worth around $1 billion today from two approved compounds and is expected to be worth $10 billion annually by 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK